Skip to Content

Nafarelin Disease Interactions

There are 4 disease interactions with nafarelin:

Major

Nafarelin nasal (Includes nafarelin) ↔ abnormal vaginal bleeding

Severe Potential Hazard, High plausibility. Applies to: Abnormal Uterine Bleeding

The use of nafarelin nasal is contraindicated in patients with undiagnosed, abnormal vaginal bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present.

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.
Moderate

Nafarelin (Includes nafarelin) ↔ seizures

Moderate Potential Hazard, Moderate plausibility. Applies to: Seizures, Brain/Intracranial Tumor, Cerebral Vascular Disorder

Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists. These have included patients with a history of seizures, epilepsy, cerebrovascular disorder, central nervous anomalies such as tumors, and patients receiving concomitant medications that have been associated with convulsions. Convulsions have also been reported in patients with none of these conditions. Caution is advised when administering nafarelin to patients with any of these conditions.

Moderate

Nafarelin nasal (Includes nafarelin) ↔ bone density loss

Moderate Potential Hazard, High plausibility. Applies to: Osteoporosis, Alcoholism

Nafarelin induces a hypoestrogenic effect that results in a small loss in bone density. Therapy with nafarelin should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids).

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.
Moderate

Nafarelin nasal (Includes nafarelin) ↔ ovarian cysts

Moderate Potential Hazard, Moderate plausibility. Applies to: Adrenal Tumor

Nafarelin therapy induces a release of pituitary gonadotropins (LH and FSH). Ovarian cysts or enlargement of existing ovarian cysts (primarily in women with polycystic ovarian disease) have been reported during the first months of treatment. Spontaneous resolution generally occurs in 4 to 6 weeks of therapy, but some cases require discontinuation of nafarelin therapy.

References

  1. "Product Information. Synarel Nasel Solution (nafarelin nasal)." Searle, Chicago, IL.

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide